diaDexus, Inc. – ‘8-K’ for 10/3/02 – EX-99.1

On:  Friday, 10/4/02, at 2:25pm ET   ·   For:  10/3/02   ·   Accession #:  1169232-2-1974   ·   File #:  0-26483

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         4      9K 
 2: EX-99.1     Press Release Issued October 3, 2002.                  3     14K 

EX-99.1   —   Press Release Issued October 3, 2002.

EX-99.1
1st Page of 3
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
Exhibit 99.1                                                                    

VaxGen Selected by U.S. Government
to Develop New Anthrax Vaccine

October 3, 2002 - Brisbane, Calif. -VaxGen Inc. (Nasdaq: VXGN), the 
current leader in AIDS vaccine development, has been awarded a contract from the
National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. 
National Institutes of Health (NIH), to develop a new anthrax vaccine and to    
create a feasibility plan to manufacture an emergency stockpile of 25 million   
doses. NIAID is expected to award a separate contract in 2003 to manufacture the
stockpile.                                                                      

  The only anthrax vaccine currently licensed, BioThrax(R), requires six
injections over 18 months. The goal of the new government contract is to develop
a vaccine that proves to be safe in humans, efficacious in animal challenge     
studies and requires no more than three injections.                             

 Under the initial phase of the NIAID contract, VaxGen will be awarded
$13.6 million to advance the development of a vaccine candidate initially       
developed by the U.S. Army Medical Research Institute of Infectious Diseases    
(USAMRIID). If results from the first phase are positive, VaxGen will be        
eligible for an additional $13.6 million in 2003 as a continuation of the       
current contract to support a Phase II clinical trial. A second, much larger    
contract to manufacture the 25-million dose stockpile will be awarded by NIAID  
through a competitive bid process next year.                                    

    "This award builds on VaxGen's expertise in the development, testing and
manufacturing of vaccines, and reflects our commitment to develop a broad array 
of biopharmaceutical products for the prevention and treatment of human         
infectious diseases," said VaxGen Chief Executive Officer Lance K. Gordon, Ph.D.
"Our objective is to meet or exceed the government's requirements and be        
selected to supply vaccine for the stockpile. If successful we would also plan  
to sell the vaccine to other approved governments and private customers."       

      As a major sub-contractor to VaxGen, Battelle of Columbus, Ohio, will have
primary responsibility for initial manufacturing of the vaccine candidate as    
well as for conducting pre-clinical safety and efficacy studies in accordance   
with FDA guidelines. VaxGen has budgeted approximately $4.5 million for         
Battelle's contributions to this urgent initiative. Battelle has substantial    
experience in biologics research and development, specifically including anthrax
vaccines.                                                                       

VaxGen will have overall responsibility for the implementation and  
management of the contract, including product design, regulatory compliance,    
design and conduct of the Phase I human clinical trial and preparation of a plan
to manufacture the 25-million dose stockpile utilizing qualified manufacturing  
operations. The plan may be based on use of VaxGen's South San Francisco        
biologics manufacturing facility, currently under                               

EX-99.1
2nd Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 2nd
development, which will also be used to manufacture up to 10 million doses per  
year of VaxGen's AIDS vaccine candidates, if they are licensed.                 

   Under an agreement with the USAMRIID, VaxGen and Battelle will continue
the development and testing of the recombinant Bacillus anthracis vaccine       
candidate known as rPA102. This investigational vaccine, developed and tested at
USAMRIID, combines the safety benefits of a vaccine made through modern         
recombinant technology with a record of efficacy documented in animal models. It
is an alum-adjuvanted, single component, recombinant protein vaccine candidate  
similar in composition to VaxGen's investigational AIDS vaccines.               

This contract has been funded in whole with Federal funds from the  
National Institute of Allergy and Infectious Diseases, National Institutes of   
Health, under Contract No. N01-A1-25494.                                        

About VaxGen                                                        

    VaxGen is focused on the commercial development of biologic products for
the prevention and treatment of human infectious diseases. It is the only       
company with AIDS vaccine candidates in Phase III clinical trials. VaxGen's two 
trials, involving nearly 8,000 volunteers in North America, Europe and Thailand,
are designed to determine if VaxGen's AIDSVAX investigational vaccines can      
prevent humans from becoming infected with HIV, the virus that causes AIDS.     
VaxGen expects to announce primary results from the first trial in the first    
quarter of 2003, with results from the second trial expected about nine months  
later.                                                                          

   VaxGen is also the major shareholder of Celltrion Inc., a joint venture
that plans to build a large-scale facility in South Korea for the manufacture of
biopharmaceutical products, including VaxGen's vaccine candidates, should they  
be licensed. VaxGen is located in Brisbane, Calif. For more information, please 
visit the company's web site at: www.vaxgen.com                                 

AIDSVAX(R) is a registered trademark of VaxGen.                     

Contacts:  Lance Ignon                                              
Vice President, Corporate Communications      
(650) 624-1016                                

Jim Key                                       
Associate Director, Corporate Communications  
(650) 624-1065                                

 ###

EX-99.1
Last Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 3rd
Note: This press release contains "forward-looking statements" within the       
meaning of the federal securities laws. These forward-looking statements include
without limitation statements regarding the progress, costs, timing and results 
of the anthrax contract with NIH; our and our subcontractors' ability to develop
a new anthrax vaccine in accordance with government specifications, or at all;  
our ability to secure a government contract to manufacture and supply an anthrax
vaccine, if development of such a vaccine were successful; the progress, costs  
and results of our Phase III clinical trials; domestic and foreign regulatory   
approvals of AIDSVAX; the ability to manufacture and supply AIDSVAX or any other
vaccine or product; our ability to commercialize AIDSVAX or any other vaccine or
product; our ability to manage our foreign manufacturing joint venture; the     
timing, and announcement of results, of either of our Phase III clinical trials,
including the timing and announcement of results from any interim analyses; our 
beliefs regarding the future success of AIDSVAX and other products currently    
under development or proposed to be developed; and the ability of our Celltrion 
joint venture to raise necessary funding for execution of its business plan.    
These statements are subject to risks and uncertainties that could cause actual 
results and events to differ materially from those anticipated. Reference should
be made to VaxGen's Quarterly Report on Form 10-Q, filed with the Securities and
Exchange Commission on August 14, 2002, under the heading "Risk Factors" and to 
VaxGen's Annual Report on Form 10-K, filed with the Securities and Exchange     
Commission on April 1, 2002, under the heading "Business" for a more detailed   
description of such factors. Readers are cautioned not to place undue reliance  
on these forward-looking statements that speak only as of the date of this      
release. VaxGen undertakes no obligation to update publicly any forward- looking
statements to reflect new information, events, or circumstances after the date  
of this release or to reflect the occurrence of anticipated events.             

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on:		10/4/02
For Period End:		10/3/02		1					424B3
		8/14/02		3					10-Q
		4/1/02		3					10-K
									List all Filings